These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31324895)

  • 1. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.
    Lee YH; Cha J; Chung SJ; Yoo HS; Sohn YH; Ye BS; Lee PH
    Sci Rep; 2019 Jul; 9(1):10531. PubMed ID: 31324895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
    Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
    J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.
    Navalpotro-Gomez I; Dacosta-Aguayo R; Molinet-Dronda F; Martin-Bastida A; Botas-Peñin A; Jimenez-Urbieta H; Delgado-Alvarado M; Gago B; Quiroga-Varela A; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2065-2076. PubMed ID: 31273436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
    Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
    Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease.
    Yoo HS; Kim HK; Lee HS; Yoon SH; Na HK; Kang SW; Lee JH; Ryu YH; Lyoo CH
    J Neurol; 2024 Aug; 271(8):5213-5222. PubMed ID: 38839638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dopamine on response inhibition in Parkinson's disease relates to age-dependent patterns of nigrostriatal degeneration.
    Kübler D; Schroll H; Hamker FH; Joutsa J; Buchert R; Kühn AA
    Parkinsonism Relat Disord; 2019 Jun; 63():185-190. PubMed ID: 30765262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease.
    Chung SJ; Lee S; Yoo HS; Lee YH; Lee HS; Choi Y; Lee PH; Yun M; Sohn YH
    J Parkinsons Dis; 2020; 10(4):1541-1549. PubMed ID: 32925098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
    Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
    Dluzen DE; McDermott JL
    J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
    Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
    Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
    Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.